1-10 of 10
Jan Baughman
Close
Sort by
Journal Articles

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Intrinsically Overcomes Factors Restricting Adoptive Cell Therapy (ACT) in Acute Myeloid Leukemia (AML)

Sergio Rutella, John Muth, Jayakumar Vadakekolathu, Tom Leedom, Alex Hamil, Laura Arthur, Nitin Mahajan, Elizabeth Schramm, Renaud Warin, Amber M Foust, David Boocock, Clare Coveney, Jan Baughman, Vincent Petit, Nupur Bhatnagar, Kristann Magee, Melissa M Berrien-Elliott, Matthew L. Cooper, Jan Davidson-Moncada, Todd A Fehniger
Journal: Blood
Blood (2023) 142 (Supplement 1): 466.
https://doi.org/10.1182/blood-2023-184923
Published: 2023
Journal Articles

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Naturally Overcomes Tumor Microenvironment (TME) Metabolic Challenges, Retaining Anti-Tumor Potency

Nupur Bhatnagar, Vincent Petit, Jayakumar Vadakekolathu, Christian Pinset, Nitin Mahajan, John Dean, Christine Spingola, Laura Arthur, David Boocock, Clare Coveney, John Muth, Jan Baughman, Melissa M Berrien-Elliott, Marc Sitbon, Matthew L. Cooper, Jan Davidson-Moncada, Todd A Fehniger, Sergio Rutella
Journal: Blood
Blood (2023) 142 (Supplement 1): 4834.
https://doi.org/10.1182/blood-2023-178868
Published: 2023
Journal Articles

A Phase 1 Study of WU-NK-101 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Amanda F. Cashen, Hongtao Liu, Monzr M. Al Malki, Joshua F. Zeidner, Matthew C. Foster, Angela Pannunzio, Brett Ramsey, Jan Baughman, John Muth, Ouiam Bakkacha, Eileen McNulty, Kenneth Jacobs, Jan K Davidson-Moncada, Andrew H Wei
Journal: Blood
Blood (2022) 140 (Supplement 1): 12740–12741.
https://doi.org/10.1182/blood-2022-158634
Published: 2022
Journal Articles

A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART ® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Pau Montesinos, MD PhD, Maria Calbacho, MD, Jordi Sierra Gil, MD PhD, Jaime Perez De Oteyza, MD PhD, Jacob M. Rowe, MB, BS, Ofir Wolach, MD, Yishai Ofran, MD, Yakir Moshe, MD, Jichao Sun, PhD, Jan Baughman, MPH, Eileen McNulty, MS, Ezio Bonvini, MD, Jon M. Wigginton, MD, Jan K Davidson-Moncada, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2662.
https://doi.org/10.1182/blood-2019-125966
Published: 2019
Journal Articles

Improvement in Cytokine Release Syndrome Management for the Treatment of AML Patients with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy

Ouiam Bakkacha, MD, Geoffrey L. Uy, MD, Ibrahim Aldoss, MD, Matthew C Foster, MD, David A Sallman, MD, Kendra L. Sweet, MD, David A. Rizzieri, MD, Peter H. Sayre, MD PhD, Anjali S. Advani, MD, Ashkan Emadi, MD, Matthew J. Wieduwilt, MD PhD, Norbert Vey, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Tamara Moyo, MD PhD, Martha L. Arellano, MD, John E. Godwin, MD, Bob Löwenberg, MD PhD, Gerwin Huls, MD PhD, Farhad Ravandi, MD, Kathy Tran, John Muth, MS, Jan Baughman, MPH, Mojca Jongen-Lavrencic, MD PhD, Erin Timmeny, Max S. Topp, MD, Stefania Paolini, MD PhD, Kuo Guo, MSc, Teia Curtis, Jian Zhao, PhD, Jon Wigginton, MD, Ezio Bonvini, MD, Roland B. Walter, MD PhD MS, Jan Davidson, John F. DiPersio, MD PhD, Kenneth Jacobs, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5144.
https://doi.org/10.1182/blood-2019-127138
Published: 2019
Journal Articles

Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart ® Molecule for T-Cell Redirected Therapy

Kenneth Jacobs, MD, Cedric Viero, PhD, John Godwin, MD, Jan Baughman, MPH, Jichao Sun, PhD, Kang Ying, John Muth, MS, Shengyan Hong, PhD, Norbert Vey, MD PhD, Kendra L. Sweet, MD, Geoffrey L. Uy, MD, Farhad Ravandi, MD, Matthew C Foster, MD, David A. Rizzieri, MD, Martha L. Arellano, MD, Michael P. Rettig, PhD, Max S. Topp, Gerwin Huls, MD PhD, Helene Lelièvre, PhD PharmD, Stefania Paolini, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Bob Lowenberg, MD, John F. DiPersio, MD PhD, Jon Wigginton, MD, Jan K Davidson-Moncada, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2738.
https://doi.org/10.1182/blood-2018-99-112615
Published: 2018
Journal Articles

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart ® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Geoffrey L. Uy, MD, Michael P. Rettig, PhD, Norbert Vey, MD PhD, John Godwin, MD, Matthew C Foster, MD, David A. Rizzieri, MD, Martha L. Arellano, MD, Max S. Topp, Gerwin Huls, MD PhD, Mojca Jongen-Lavrencic, MD PhD, Giovanni Martinelli, MD, Stefania Paolini, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Kendra L. Sweet, MD, Farhad Ravandi, MD, Sarah E. Church, PhD, Jayakumar Vadakekolathu, PhD, Sergio Rutella, MD PhD FRCPath, Jichao Sun, PhD, Kang Yang, Jan Baughman, MPH, Teia Curtis, PhD, Erin Timmeny, Kerri Cali, Kathy Tran, John Muth, MS, Ross La Motte-Mohs, PhD, Camille Poirot, Pharm.D., Athanasios Pallis, MD, Alessandra Cesano, MD PhD, Ezio Bonvini, MD, Jon Wigginton, MD, Bob Lowenberg, MD, Jan K Davidson-Moncada, MD PhD, John F. DiPersio, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 764.
https://doi.org/10.1182/blood-2018-99-117085
Published: 2018
Journal Articles

Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies

Michael P Rettig, PhD, John Godwin, MD, Norbert Vey, Bernard Fox, PhD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Daner Li, MS, Daniel Primo, PhD, Joan Ballesteros, PhD, Jichao Sun, PhD, Helene Lelièvre, PhD PharmD, Jan Baughman, MPH, Ross La Motte-Mohs, PhD, John Muth, MS, Paul Moore, PhD, Ezio Bonvini, MD, Jon Wigginton, John F DiPersio, MD PhD, Jan Davidson-Moncada, MDPhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1365.
https://doi.org/10.1182/blood.V130.Suppl_1.1365.1365
Published: 2017
Journal Articles

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Geoffrey L. Uy, MD, John Godwin, MD, Michael P Rettig, PhD, Norbert Vey, Matthew Foster, Martha L. Arellano, MD, David A. Rizzieri, MD, Max S. Topp, MD, Gerwin Huls, MD PhD, Bob Lowenberg, MD PhD, Giovanni Martinelli, MD, Stefania Paolini, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Helene Lelièvre, PhD PharmD, Ross La Motte-Mohs, PhD, Daner Li, MS, Jichao Sun, PhD, Kenneth Jacobs, MD, Karen Spohn, BS, Nadia Lonsdale, BA, Kathy Tran, Jan Baughman, MPH, Michele Shannon, PhD, Bernard Fox, PhD, Ezio Bonvini, MD, Jon Wigginton, Jan Davidson-Moncada, MD, John F DiPersio, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 637.
https://doi.org/10.1182/blood.V130.Suppl_1.637.637
Published: 2017
Journal Articles

Lead-in Dose Optimization to Mitigate Cytokine Release Syndrome in AML and MDS Patients Treated with Flotetuzumab, a CD123 x CD3 Dart® Molecule for T-Cell Redirected Therapy

Kenneth Jacobs, MD, John Godwin, MD, Matthew Foster, Norbert Vey, Geoffrey L. Uy, MD, David A. Rizzieri, MD, Martha L. Arellano, MD, Michael P Rettig, PhD, Stephanie Christ, MS, Max S. Topp, MD, Geert Huls, MD PhD, Bob Lowenberg, MD PhD, Giovanni Martinelli, MD, Stefania Paolini, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Jichao Sun, PhD, Daner Li, MS, Kathy Tran, Karen Spohn, BS, Jan Baughman, MPH, Sadhna Shankar, MDMPH, Helene Lelièvre, PhD PharmD, Ezio Bonvini, MD, John F DiPersio, MD PhD, Jon Wigginton, Jan K davidson-Moncada, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3856.
https://doi.org/10.1182/blood.V130.Suppl_1.3856.3856
Published: 2017